The positive Part 2 results materially improve the risk/reward for obefazimod's NDA submission in Q4 2026. Traders should monitor for FDA acceptance and potential advisory committee meeting. Given prior volatility (T+20 avg -10.2% on prior neutral reads), consider taking partial profits on strength and re-entering on any pullback ahead of the NDA catalyst.
Price Chart
Executive Summary
Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission in induction non-responders and 45.5% recapture of remission in relapsers. The expanded safety database (1,704 patient-years) showed malignancy rates consistent with UC background rates. The company remains on track for NDA submission in Q4 2026.
Key Facts
- 37.2% of induction non-responders achieved clinical remission at Week 44 on 50 mg obefazimod
- 45.5% of patients who relapsed on 25 mg and escalated to 50 mg recaptured clinical remission
- Exposure-adjusted malignancy rates (excluding NMSC) were 0.35 per 100 PY in all-active combined, within UC background range of 0.30–0.70
- NDA submission for obefazimod in UC remains on track for Q4 2026
- Integrated safety database includes 1,704 patient-years of exposure across Phase 2 and Phase 3 programs
Financial Impact
Positive Phase 3 maintenance data strengthens NDA package and de-risks approval path for obefazimod, a potential blockbuster UC therapy. Stock price reaction likely significant given prior safety concerns are addressed with expanded dataset.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) despite expanded safety data
- Competition from existing and emerging UC therapies (JAK inhibitors, IL-23 blockers) could limit commercial uptake
- Long-term safety monitoring continues; any new signal could derail approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | $94.17 (−27.56%) |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | $94.17 (+28.96%) |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | $94.17 (−25.50%) |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | $94.17 (−14.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access